Gastro-oesophageal reflux disease in chronic laryngitis: prevalence and response to acid-suppressive therapy.

Abstract:

BACKGROUND:Gastro-oesophageal reflux is thought to cause chronic laryngitis through laryngopharyngeal reflux. Response of laryngitis to treatment with acid-suppressive therapy supports this causal link. AIM:To determine the prevalence of gastro-oesophageal reflux disease in patients with chronic laryngitis and response to proton-pump inhibitor therapy. METHODS:Patients with chronic laryngitis were recruited. The frequency and severity of reflux and laryngeal symptoms were scored and laryngitis graded by laryngoscopy. All patients underwent esophagogastroduodenoscopy and 24-h ambulatory pH monitoring before receiving lansoprazole 30 mg b.d. for 8 weeks. RESULTS:The prevalence of gastro-oesophageal reflux disease was 65.6% (21 of 32). Based on positive pH test, the prevalence was 25% (eight of 32). The change in laryngeal symptom score and laryngitis grade was significantly higher in GERD compared with non-GERD patients (P = 0.010 for both). The proportion of patients with marked/moderate improvement in laryngeal symptoms were significantly higher in patients with reflux (14 of 21, 67%) compared to those without reflux (two of 11, 18%; P = 0.026). CONCLUSIONS:The prevalence of gastro-oesophageal reflux disease amongst our patients with chronic laryngitis was high. The response to treatment with proton-pump inhibitors in patients with reflux disease compared to those without underlined the critical role of acid reflux in a subset of patients with chronic laryngitis.

journal_name

Aliment Pharmacol Ther

authors

Qua CS,Wong CH,Gopala K,Goh KL

doi

10.1111/j.1365-2036.2006.03185.x

subject

Has Abstract

pub_date

2007-02-01 00:00:00

pages

287-95

issue

3

eissn

0269-2813

issn

1365-2036

pii

APT3185

journal_volume

25

pub_type

杂志文章
  • Systematic review: macrophage activation syndrome in inflammatory bowel disease.

    abstract:BACKGROUND:Recently, there have been increasingly frequent reports on the occurrence of macrophage activation syndrome (MAS) in patients with inflammatory bowel disease (IBD). Clinically, MAS is characterized mainly by fever, hepatosplenomegaly, cytopenia, and elevated circulating ferritin and CD25. Mortality, even if ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.12305

    authors: Fries W,Cottone M,Cascio A

    更新日期:2013-06-01 00:00:00

  • Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk.

    abstract:BACKGROUND:Low bone mineral density (BMD) has been reported in both paediatric and adult patients with non-alcoholic fatty liver disease (NAFLD). The mechanisms behind the reduced BMD in NAFLD are still not completely understood. AIM:To provide a critical overview of the pathophysiological pathways linking NAFLD, redu...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2012.05196.x

    authors: Yilmaz Y

    更新日期:2012-08-01 00:00:00

  • Characteristics of patients with irritable bowel syndrome recruited from three sources: implications for clinical trials.

    abstract:BACKGROUND:Variation in the characteristics of irritable bowel syndrome patients recruited for clinical trials from different sources could affect their response and the generalizability of trial results. AIM:To describe and compare the characteristics of three different groups of irritable bowel syndrome patients rec...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2001.01010.x

    authors: Longstreth GF,Hawkey CJ,Mayer EA,Jones RH,Naesdal J,Wilson IK,Peacock RA,Wiklund IK

    更新日期:2001-07-01 00:00:00

  • The effect of rebamipide on the expression of proinflammatory mediators and apoptosis in human neutrophils by Helicobacter pylori water-soluble surface proteins.

    abstract:BACKGROUND:Helicobacter pylori infection elicits persistent neutrophil infiltration in gastric mucosa. The expression of cyclooxygenase (COX)-2 and inhibition of apoptosis in the neutrophils could contribute to the pathogenesis of H. pylori infection. Rebamipide, a mucosal protective and ulcer-healing drug, has been kn...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.18.s1.1.x

    authors: Kim JS,Kim JM,Jung HC,Song IS

    更新日期:2003-07-01 00:00:00

  • Haemodynamic responses to 1.25 and 2 mg of terlipressin intravenously in man.

    abstract::The systemic and hepatic haemodynamic effects following terlipressin (Glypressin) administration were studied. Bolus intravenous injections of 1.25 and 2 mg significantly decreased wedged hepatic vein pressure gradient by 29% and 31%, respectively. With each dose there was a small increase in mean arterial blood press...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1988.tb00709.x

    authors: Freeman JG,Barton JR,Record CO

    更新日期:1988-08-01 00:00:00

  • A 6-month, open-label clinical trial of pancrelipase delayed-release capsules (Creon) in patients with exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery.

    abstract:BACKGROUND:Pancreatic enzyme replacement therapy (PERT) is necessary to prevent severe maldigestion and unwanted weight loss associated with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). AIM:To assess the long-term safety and efficacy of pancrelipase (pancreatin) ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2011.04631.x

    authors: Gubergrits N,Malecka-Panas E,Lehman GA,Vasileva G,Shen Y,Sander-Struckmeier S,Caras S,Whitcomb DC

    更新日期:2011-05-01 00:00:00

  • The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.

    abstract:BACKGROUND:Helicobacter pylori eradication improves dyspeptic symptoms in 8%-10%, prevents peptic ulcer and may reduce the risk of gastric cancer. Availability of a high quality diagnostic test and an effective treatment makes population screening and eradication of Helicobacter pylori an attractive option. AIM:To eva...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/apt.15193

    authors: Høgh MB,Kronborg C,Hansen JM,Schaffalitzky de Muckadell OB

    更新日期:2019-04-01 00:00:00

  • Classification of dyspepsia and response to treatment with proton-pump inhibitors.

    abstract:BACKGROUND:Lacking an objective 'gold standard' for diagnosing dyspepsia, several symptom-based classifications have been suggested. AIM:To assess if response to proton-pump inhibitor treatment could provide useful information for current or future dyspepsia classification. METHODS:Post hoc analyses of 829 patients t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2004.02243.x

    authors: Meineche-Schmidt V

    更新日期:2004-11-15 00:00:00

  • Review article: management of hepatic disease following haematopoietic cell transplant.

    abstract::Hepatic diseases are common complications of haematopoietic cell transplant. The causes are multiple: myeloablative conditioning regimens may cause sinusoidal injury; acute and chronic graft-versus-host disease lead to damaged hepatocytes and small bile ducts; microcrystalline deposits in the gall bladder can cause bi...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.03001.x

    authors: McDonald GB

    更新日期:2006-08-01 00:00:00

  • Review article: the opportunities and benefits of extended acid suppression.

    abstract::Acid suppression therapy with proton pump inhibitors is associated with well-established benefits in the management of gastro-oesophageal reflux (GERD) and other acid-related disorders. However, a number of issues still remain unsettled. Despite their clinical efficacy, when given once daily, currently available proto...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.02945.x

    authors: Scarpignato C,Pelosini I

    更新日期:2006-06-01 00:00:00

  • Non-Helicobacter pylori gastritis is common among paediatric patients with inflammatory bowel disease.

    abstract:BACKGROUND:Helicobacter-negative gastritis and duodenitis occur more often in patients with inflammatory bowel disease (IBD) than in non-IBD controls. Preliminary evidence suggests that they are particularly common among children. AIM:To study the age-specific occurrence of gastritis and duodenitis among paediatric IB...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2012.05090.x

    authors: Genta RM,Sonnenberg A

    更新日期:2012-06-01 00:00:00

  • Review article: can post-operative recurrence in Crohn's disease be prevented?

    abstract::The decision regarding prophylactic treatment after surgery in Crohn's disease (CD) requires a good estimation of the risk of recurrence. It is also important to consider the consequences of recurrence for the patient, and the risks and benefits of treatment, bearing in mind that it will be given over a long period. S...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2006.03055.x

    authors: Lémann M

    更新日期:2006-10-01 00:00:00

  • Randomised clinical trial: the efficacy and safety of pancreatin enteric-coated minimicrospheres (Creon 40000 MMS) in patients with pancreatic exocrine insufficiency due to chronic pancreatitis--a double-blind, placebo-controlled study.

    abstract:BACKGROUND:Pancreatic exocrine insufficiency (PEI) results in maldigestion, leading to abdominal pain, steatorrhoea, malnutrition and weight loss. AIM:To assess the efficacy and safety of pancreatin (Creon 40000 MMS) in treating PEI due to chronic pancreatitis (CP). METHODS:This was a 1-week, double-blind, randomised...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2012.05202.x

    authors: Thorat V,Reddy N,Bhatia S,Bapaye A,Rajkumar JS,Kini DD,Kalla MM,Ramesh H

    更新日期:2012-09-01 00:00:00

  • Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.

    abstract:BACKGROUND:One-week triple therapy consisting of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. is an effective therapy for H. pylori infection with a cure rate of 93%. We therefore compared two similar 1-week regimens consisting of a lansoprazole, clarithromycin and either metronidazole o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.0953-0673.1996.00275.x

    authors: Jaup BH,Norrby A

    更新日期:1996-06-01 00:00:00

  • The effect of trospium chloride on oesophageal motility.

    abstract::Trospium chloride is a muscarinergic antagonist acting on oesophageal smooth muscle and on ganglionic and/or myenteric neurons. The effect of this drug on oesophageal motility was tested in 16 healthy male subjects in a double-blind randomized cross-over examination of trospium chloride or placebo following phentolami...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1993.tb00072.x

    authors: Frieling T,Enck P,Dohmann R,Wienbeck M,Lübke HJ

    更新日期:1993-02-01 00:00:00

  • Review Article: pain versus discomfort--is differentiation clinically useful?

    abstract::Functional dyspepsia is highly variable in its clinical presentation and multifactorial in its underlying causes. Since many of the symptoms included in the definition of dyspepsia are intuitively suggestive of different pathogenic mechanisms, it has been proposed that patients with functional dyspepsia be divided int...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2001.00906.x

    authors: Stanghellini V

    更新日期:2001-02-01 00:00:00

  • Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment.

    abstract:AIM:To compare cheaper and simpler once-daily regimens, with and without a proton pump inhibitor, with standard, twice-daily, triple therapy. METHODS:A randomized, placebo-controlled, treatment trial in Vietnam allocated 296 Helicobacter pylori-infected patients with peptic ulcer of >or= 5 mm to one of three regimens:...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2003.01649.x

    authors: Wheeldon TU,Hoang TT,Phung DC,Björkman A,Granström M,Sörberg M

    更新日期:2003-07-01 00:00:00

  • Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong.

    abstract:BACKGROUND:Clinical features of hepatocellular carcinoma patients are changing because of screening. AIM:To examine the clinical features of hepatocellular carcinoma patients in Hong Kong and validity of different staging systems. METHODS:A total of 223 Chinese patients with hepatocellular carcinoma were studied. RE...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03029.x

    authors: Cheung TK,Lai CL,Wong BC,Fung J,Yuen MF

    更新日期:2006-08-15 00:00:00

  • Hepatitis E virus in patients with decompensated chronic liver disease: a prospective UK/French study.

    abstract:BACKGROUND:In developed countries, hepatitis E is a porcine zoonosis caused by hepatitis E virus (HEV) genotype 3. In developing countries, hepatitis E is mainly caused by genotype 1, and causes increased mortality in patients with pre-existing chronic liver disease (CLD). AIM:To determine the role of HEV in patients ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13309

    authors: Blasco-Perrin H,Madden RG,Stanley A,Crossan C,Hunter JG,Vine L,Lane K,Devooght-Johnson N,Mclaughlin C,Petrik J,Stableforth B,Hussaini H,Phillips M,Mansuy JM,Forrest E,Izopet J,Blatchford O,Scobie L,Peron JM,Dalton H

    更新日期:2015-09-01 00:00:00

  • Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?

    abstract:BACKGROUND:There is clear benefit from combination therapy with infliximab and immunosuppressive drugs (IS), but few data are available for adalimumab (ADA). AIM:To assess the efficacy of ADA monotherapy and ADA+IS for induction and maintenance therapy in Crohn's disease. METHODS:Retrospective study of patients with ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12076

    authors: Reenaers C,Louis E,Belaiche J,Seidel L,Keshav S,Travis S

    更新日期:2012-12-01 00:00:00

  • Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture.

    abstract:BACKGROUND:There has been increasing interest in small intestinal bacterial overgrowth (SIBO) after reports of a link with irritable bowel syndrome (IBS), yet our understanding of this entity is limited. AIM:Our aim was to estimate the yield of patients undergoing duodenal aspirate culture, and to identify symptoms an...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04625.x

    authors: Choung RS,Ruff KC,Malhotra A,Herrick L,Locke GR 3rd,Harmsen WS,Zinsmeister AR,Talley NJ,Saito YA

    更新日期:2011-05-01 00:00:00

  • Dyspepsia workload in urban general practice and implications of the British Society of Gastroenterology Dyspepsia guidelines (1996).

    abstract:AIM:To define the characteristics of patients consulting with active dyspeptic symptoms in urban general practice, and to consider the implications of applying the British Society of Gastroenterology Dyspepsia management guidelines. DESIGN:Prospective observational study over a period of 12 months. SETTING:Two multip...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2000.00728.x

    authors: Bodger K,Eastwood PG,Manning SI,Daly MJ,Heatley RV

    更新日期:2000-04-01 00:00:00

  • Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease.

    abstract:BACKGROUND:Adverse events leading to discontinuation or dose reduction of thiopurine therapy occur in 9-28% of patients with inflammatory bowel disease. AIMS:To evaluate the influence of thiopurine methyltransferase status and thiopurine metabolites in a large patient population for the risk of developing adverse even...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/j.1365-2036.2006.02977.x

    authors: Hindorf U,Lindqvist M,Hildebrand H,Fagerberg U,Almer S

    更新日期:2006-07-15 00:00:00

  • Earlier discontinuation of TNF-α inhibitor therapy in female patients with inflammatory bowel disease is related to a greater risk of side effects.

    abstract:BACKGROUND:In rheumatoid arthritis and psoriasis female sex has been shown to be associated with discontinuation of anti-tumour necrosis factor-α (TNF-α) therapy. AIM:To retrospectively assess the association between sex and TNF-α drug persistence in patients with inflammatory bowel disease (IBD). METHODS:All IBD pat...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15380

    authors: Schultheiss JPD,Brand EC,Lamers E,van den Berg WCM,van Schaik FDM,Oldenburg B,Fidder HH

    更新日期:2019-08-01 00:00:00

  • Review article: functional dyspepsia--should treatment be targeted on disturbed physiology?

    abstract::In patients who present with chronic unexplained upper abdominal pain or discomfort (functional dyspepsia), therapy should ideally be targeted on correcting the individual's disturbed pathophysiology. Here, putative mechanisms implicated in functional dyspepsia and potential approaches to therapy are critically review...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1995.tb00359.x

    authors: Talley NJ

    更新日期:1995-04-01 00:00:00

  • Acute liver failure in Scotland: changes in aetiology and outcomes over time (the Scottish Look-Back Study).

    abstract:BACKGROUND:Acute liver failure is a rare and devastating clinical condition resulting from sudden loss of hepatic parenchyma and metabolic function. The Scottish Liver Transplant Unit (SLTU) offers specialist management and emergency liver transplantation to patients with acute liver failure from across Scotland. AIM:...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13943

    authors: Donnelly MC,Davidson JS,Martin K,Baird A,Hayes PC,Simpson KJ

    更新日期:2017-03-01 00:00:00

  • Review article: reflux and its consequences--the laryngeal, pulmonary and oesophageal manifestations. Conference held in conjunction with the 9th International Symposium on Human Pepsin (ISHP) Kingston-upon-Hull, UK, 21-23 April 2010.

    abstract:BACKGROUND:Gastro-oesophageal reflux disease (GERD) is one of the commonest diseases of Western populations, affecting 20 to 30% of adults. GERD is multifaceted and the classical oesophageal symptoms such as heartburn and regurgitation often overlap with atypical symptoms that impact upon the respiratory system and air...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2011.04581.x

    authors: Pearson JP,Parikh S,Orlando RC,Johnston N,Allen J,Tinling SP,Johnston N,Belafsky P,Arevalo LF,Sharma N,Castell DO,Fox M,Harding SM,Morice AH,Watson MG,Shields MD,Bateman N,McCallion WA,van Wijk MP,Wenzl TG,Karkos

    更新日期:2011-04-01 00:00:00

  • Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.

    abstract:AIM:: To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5-aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro-drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2003.01408.x

    authors: Sandborn WJ,Hanauer SB

    更新日期:2003-01-01 00:00:00

  • Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

    abstract:BACKGROUND:Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM:To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma. METH...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15245

    authors: Scheiner B,Kirstein MM,Hucke F,Finkelmeier F,Schulze K,von Felden J,Koch S,Schwabl P,Hinrichs JB,Waneck F,Waidmann O,Reiberger T,Müller C,Sieghart W,Trauner M,Weinmann A,Wege H,Trojan J,Peck-Radosavljevic M,Vogel A

    更新日期:2019-05-01 00:00:00

  • Double-blind comparison of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid suppositories in patients with idiopathic proctitis.

    abstract::Suppositories containing 300 mg 5-aminosalicylic acid (1.96 mmol) or 425 mg acetyl-5-aminosalicylic acid (1.96 mmol) were used in 40 patients with idiopathic proctitis to determine the efficacy of acetyl-5-aminosalicylic acid in treating this bowel inflammation. Each patient was treated with 5-aminosalicylic acid or a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1988.tb00668.x

    authors: van Hogezand RA,van Hees PA,van Gorp JP,van Lier HJ,Bakker JH,Wesseling P,van Haelst UJ,van Tongeren JH

    更新日期:1988-02-01 00:00:00